TrialScope, Vivli join forces to address transparency for clinical trial sponsors and researchers

▤ Summary

“There is a growing trend towards increased transparency within the clinical trial industry, not just to meet regulatory requirements, but as an ethical obligation to advance science and promote patient safety,” said TrialScope CEO Jeff Kozloff in a statement. We appreciate the fact that Vivli is disease agnostic and can synthesize data from multiple repositories, which will greatly reduce duplication of clinical trials, putting fewer patients through studies unnecessarily,” said Kozloff. “We are delighted to partner with TrialScope, which is recognized as the leader in clinical trial disclosure,” said Rebecca Li, executive director of Vivli. TrialScope said that its SaaS-based, centralized approach has met the disclosure and transparency needs of the trial industry from large pharmaceutical companies (13 of the top 15) to smaller biotech firms for more than five years. The alliance, according to TrialScope, draws on complementary strengths of each partner and will deliver an opportunity for sponsors to address their disclosure and transparency needs including: Disclosure and data-sharing software and advisory services; technology to help people find help people find relevant, authoritative clinical trial information online; the ability to host anonymized individual participant data; and the ability for sponsors to share their data in a secure research environment.

▦ Linked Companies

TrialScope

$10M to $25M